Werner A, Krebs D, Diedrich K, Fimmers R, Heuer J, Oberheuser F
Frauenklinik, Universität Bonn.
Geburtshilfe Frauenheilkd. 1990 Nov;50(11):883-9. doi: 10.1055/s-2008-1026386.
Since 1982, chemosensitivity studies have been conducted in our laboratory with 181 tumour samples from 132 woman patients suffering from carcinoma of the ovaries, using the colony test and capillary assays. Colonisation rates were 67% and assay rates between 60 and 47%; in 36 cases the in vitro result was compared with the course of the disease observed in vivo. Whereas in 11 of 12 patients it was possible to correctly assess chemoresistance (in vitro growth inhibition less than or equal to 49%) pretherapeutically, chemosensitivity (growth inhibition greater than or equal to 50%) proved more difficult to confirm, 15 predictions being true and 9 false. To assess the prognostic significance of the test results, survival curves were calculated from the data of 33 patients. With a p-value of 0.49, the courses of disease of "in vitro resistant" and "in vitro sensitive" patients differed only slightly from one another. We can conclude from our experiments, that an important indication for performing the colony test in ovarian carcinoma should always be assumed in patients with a poor prognosis, e.g. in women having a large postoperative residual tumour. If, in such cases, the possibility of chemosensitivity testing via the colony test is considered, this examination may offer the chance of sparing the patient additional strain due to the side effects of a treatment with cytostatics if the latter is most likely to be of no significant use.
自1982年以来，我们实验室使用集落试验和毛细管分析方法，对132例卵巢癌女性患者的181份肿瘤样本进行了化学敏感性研究。集落形成率为67%，分析率在60%至47%之间；在36例病例中，将体外结果与体内观察到的疾病进程进行了比较。在12例患者中有11例能够在治疗前正确评估化疗耐药性（体外生长抑制小于或等于49%），而化疗敏感性（生长抑制大于或等于50%）则更难确认，15次预测正确，9次错误。为了评估检测结果的预后意义，根据33例患者的数据计算了生存曲线。p值为0.49，“体外耐药”和“体外敏感”患者的疾病进程彼此之间仅略有差异。我们可以从实验中得出结论，对于预后不良的患者，例如术后残留肿瘤较大的女性，应始终将其视为进行卵巢癌集落试验的重要指征。如果在这种情况下考虑通过集落试验进行化疗敏感性检测，那么如果细胞毒性药物治疗很可能没有显著效果，这项检查可能会为患者提供避免因细胞毒性药物治疗的副作用而承受额外负担的机会。
